IPM Take
The important move is location. Duke is not waiting for diabetes patients to book and attend separate ophthalmology visits. It is bringing AI retinal screening into endocrinology clinics, where many patients already receive care. That is a practical access lesson: for chronic disease complications, the best screening pathway may be the one that removes an extra appointment, not the one with the most advanced technology.
Executive Summary
Duke Eye Center announced that it would launch an institution-wide AI-powered diabetic retinopathy screening programme in May 2026. The programme brings retinal screening into endocrinology clinics using FDA-cleared AI retinal imaging technology. Trained clinic staff capture retinal photographs without dilation, the AI system returns results in around 30 seconds, and patients with detected diabetic retinopathy can be referred immediately to ophthalmology. Duke says the initial rollout will take place in two high-volume endocrinology clinics, with outcomes, adherence and cost-effectiveness monitored.
Why it matters
- Hospitals / providers: Can improve screening access by embedding diagnostics inside diabetes care rather than relying only on separate ophthalmology appointments.
- Clinicians: Need workflows that define who is screened, how results are explained and when patients are referred to ophthalmology.
- Patients / advocates: Should watch whether clinic-based screening improves adherence and reduces missed eye exams, especially for patients facing access barriers.
Previously, many people with diabetes were expected to attend separate annual eye examinations, even while managing multiple chronic-care appointments. Duke notes that more than half of people with diabetes in the United States do not receive regular eye exams.
What changed is the clinic model. Screening is embedded in diabetes care instead of being treated as a separate specialist pathway. Trained endocrinology clinic staff capture non-dilated retinal images, and the AI system provides results in about 30 seconds. Patients with diabetic retinopathy can then be referred immediately to ophthalmology.
The affected group is patients with diabetes who need routine diabetic retinopathy screening. This is not a general eye-screening programme for the whole population. It is a workflow redesign for a known diabetes complication.
For IPM, the message is sharp: implementation can be personalised by workflow. If screening is placed where patients already are, access can improve before disease becomes vision-threatening.
